Ian McElree

Urology resident at @VUMCUrology by way of @Iowamed. RT, like, follow does not = endorsement.

[University of Iowa Urology @UIowa_urology]

New in @EurUrolFocus: Extended Outcomes of Intravesical Valrubicin and Docetaxel as a Secondary Salvage Treatment for Recalcitrant High-risk Non-muscle-invasive Bladder Cancer. https://t.co/gn1zkPdG3e

#MikeODonnell @HougenHY @ryansteinbergmd

[Ryan L. Steinberg MD @ryansteinbergmd]

More great work by @IanMcelree on the importance of bluelight & checking sanctuary sites in post induction HR NMIBC. Esp 🔑 when considering multiple rounds of salvage therapy!

@HougenHY @VigneshPackiam #MikeODonnell @UIowa_urology

https://t.co/Fyw7w76CIU

[University of Iowa Urology @UIowa_urology]

New in @EurUrolOncol, including @UIowa_urology authors Dr. Michael A. O'Donnell, Dr. Jordan R. Richards, and @IanMcelree: Investigation of first AI-powered histologic biomarker for patients with untreated high-grade NMIBC: https://t.co/vc07C2Okzr

[Valar Labs @valarlabs]

We are thrilled to share our recent publication in @EurUrolOncol demonstrating for the first time CHAI based predictive biomarker to guide use of intravesical BCG vs alternatives (chemotherapy). In an era of BCG shortage and new alternatives to BCG incoming, precision medicine based tools to guide intravesical treatment choice will enable improved patient care in bladder cancer.

Incredible collaborative effort with bladder cancer experts @VigneshPackiam @pjhensley11 @UroDocAsh @saumyg @SWilliams_MD @IanMcelree @YairLotan

https://t.co/zgpiWHRZme

[Ryan L. Steinberg MD @ryansteinbergmd]

Fantastic work by super ⭐️ @IanMcelree presenting @UIowa_urology data on restaging procedures for NMIBC. An important step when considering multiple salvage intravesical therapies. Keep an eye out for him in this year’s match! #NCSAUA24

@NCSAUA @VigneshPackiam

[Yousef Zakharia @ZakhariaYousef]

Another intravesicular regimen (cabazitaxel+ Gem) by Mike O'Donnell @UIowaCancer with pembro, in refractory HRNMIBC (Doce failure), interesting results, prospective study underway. Honored to be part of this effort.
https://t.co/WKFCE7pRDh #mdpicancers via @Cancers_MDPI

[Vignesh Packiam, MD @VigneshPackiam]

Nice paper @ReubenBenDavid1 @DrJohnSfakianos !! Important to learn optimal Gem/Doce protocol. Data like this on the implications of maintenance are valuable. Anecdotally I have found that 2g Gem in combo regimens has more tol issues @saumyg @RutgersCancer @rwjurology @IanMcelree

[Ryan L. Steinberg MD @ryansteinbergmd]

Fantastic work by @IanMcelree (as always!) presenting on BCG vs Gem/Doce in upper tract CIS. Similar outcomes with regards to RFS/NFS/OS. But be careful of the potential for infection!

#AUA24 #SaveTheNephrons #GemDoce #UTUC

@VigneshPackiam @UIowa_urology

[Ian McElree @IanMcelree]

@WadeRGutierrez @MayoUrology Couldn’t be happier for you, Wade!!

[Wade R. Gutierrez, MD, PhD @WadeRGutierrez]

Ecstatic and humbled to be joining @MayoUrology for residency! What a dream come true. Rochester, here we come! 🎉🎉🎉

#auamatch #uromatch #urosome #IowaMatch2024

[Ryan L. Steinberg MD @ryansteinbergmd]

Such a privilege to continue working with @IanMcelree on use of endoluminal Gem/Doce, now for #UTUC

Takeaways:
🟡 41 upper tracts - 90% CIS (most had + cytology)
🟡 2 yr-RFS 54%, 2yr-NephUFS 92%
🟡 👤 selection is 🔑

#GemDoce #SaveTheNephrons 

@VigneshPackiam @UIowa_urology

[Ryan L. Steinberg MD @ryansteinbergmd]

💥New 📝 Alert💥

Gem/Doce for HG Favorable UTUC

📍41 UT units, 90% CIS (+cytology)
📍2yr RFS 54%, 3yr PFS 75%
📍2 yr NephU Free 92%
🛑 5 pts died of UTUC

Reasonable option 4 selected patients!

https://t.co/b2rdzrnfS6

@UIowa_urology @VigneshPackiam @IanMcelree #MikeODonnell

[Vignesh Packiam, MD @VigneshPackiam]

Continued great work by super 🌟 @IanMcelree

Gem/Doce effective in treatment naive (79% 2 year RFS) and previously treated (64%) Intermediate Risk NMIBC
@ryansteinbergmd @JOrzel_MD @BladderCancerUS @SUO_YUO

Can be considered for various disease states

https://t.co/Kel2zb8xTz

[Wei Shen Tan @drtanws]

Pooling together patients from @MDAndersonNews @MoffittNews @uiowa we report outcomes of IR-NMIBC patients treated with Gem-Doce vs BCG in @EurUrolOncol

@IanMcelree @FDavaro @ryansteinbergmd @KKBree @nnavai #ColinDinney #MikeODonnell @UrogerliMD @UroDocAsh @VigneshPackiam

[Vignesh Packiam, MD @VigneshPackiam]

Really impactful science @LauraBukavinaMD - you are awesome work with!

Gem/Doce 📈📈📈 this is great for our patients

Important translational work in the works @IanMcelree @MaxKates @eugene_pietzak @saumyg @BladderCancerUS

[Laura Bukavina @LauraBukavinaMD]

Someday soon enough bcg is not going to be the standard of care #nmibc … alternative therapies are coming . In the meantime I’ll keep sending my napkin results to @VigneshPackiam and our 🐁 results .. 40% CR Gem Doce / 40 % CR alternative 🦠 .. bcg 👎🏻 #bladdercancer

[Ian McElree @IanMcelree]

What an honor - Thanks @JUrology for recognizing our work 🫡 Still much to be done! @VigneshPackiam @ryansteinbergmd

[Ian McElree @IanMcelree]

Change is good!

[Vignesh Packiam, MD @VigneshPackiam]

As usual a killer presentation by @IanMcelree about Gem/Doce for intermediate risk NMIBC @DrMBWesterman @gershmanMD @UIowa_urology #AUA23

79% 2 year complete response in treatment naive

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

Further evidence that Gem/Doce is reasonable alternative to BCG in patients with high-risk NMIBC, during the ongoing BCG shortage @IanMcelree @VigneshPackiam @ryansteinbergmd @uiowa

https://t.co/8oNlbhzpSs @JAMANetworkOpen @JAMANetwork

#Bridge Trial @MaxKates @angiesmith_uro

[JAMA Network Open @JAMANetworkOpen]

Gem+Doce is associated with better 2yr high-grade recurrence-free survival (81% vs 69%), less treatment discontinuation (3% vs 9%) vs BCG in patients with non–muscle-invasive bladder cancer; may be useful during BCG shortage. @VigneshPackiam @IanMcElree https://t.co/rWtXEz494B